Mayo Clinic-connected Cardio3 Biosciences raises $24 million - PostBulletin.com: Local Business

Mayo Clinic-connected Cardio3 Biosciences raises $24 million

Print
Font Size:
Default font size
Larger font size

Posted: Tuesday, May 14, 2013 8:21 am

Cardio3 BioSciences, the biotechnology firm based on Mayo Clinic research with U.S. headquarters in Rochester, recently raised $24 million in financing to continue the development of its treatment designed to regenerate parts of a patient's heart.

In its announcement, the Belgium-based company reported that it plans to use this latest round of financing for the Phase III clinical trial of its C-Cure product underway in Europe. Cardio3 describes it as "…The world's first phase III trial using pre-programmed cardiac progenitor cells and targeting heart failure."

Subscription Required

An online service is needed to view this article in its entirety. You need an online service to view this article in its entirety.

Have an online subscription?

Login Now

Need an online subscription?

Subscribe

Login

You must login to view the full content on this page.

Thank you for reading 7 free articles on our site. You can come back at the end of your 30-day period for another 7 free articles, or you can purchase a subscription and continue to enjoy valuable local news and information. If you need help, please contact our office at 800-562-1758 . You need an online service to view this article in its entirety.

Have an online subscription?

Login Now

Need an online subscription?

Subscribe

Login

Featured Ads

Follow us on Facebook  Follow us on Twitter  RSS Feeds       RSS Feeds 


Feb 13 | No Comments
Feb 12 | No Comments
Feb 13 | No Comments
Feb 8 | No Comments
Feb 12 | No Comments
Feb 13 | No Comments
Feb 11 | No Comments
Feb 12 | No Comments
Feb 13 | No Comments

More News

Visit our other local news sites:
Daily-Journal.com -- Kankakee, IL
QCOnline.com -- Moline, IL
MyWebTimes.com -- Ottawa, IL